A Phase II 12-month open-label study of ACH-4471 for patients with biopsy-confirmed C3G or IC-MPGN.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 07 Nov 2017 New trial record
- 02 Nov 2017 According to Achillion media release, company plans to initiate the trial in first half of 2018.